AtaiBeckley的EMP-01减轻了49%具有良好安全特征的病人的社会焦虑,这显示了提供新治疗的希望。 AtaiBeckley's EMP-01 reduced social anxiety in 49% of patients with a good safety profile, showing promise for a new treatment.

AtaiBeckley Inc.报告说,其口服R-MDMA治疗(EMP-01)为社会焦虑症进行的第2阶段试验取得了积极的成果,49%的参与者表现出了有利的安全状况和有意义的症状改善。 AtaiBeckley Inc. reported positive topline results from a Phase 2a trial of its oral R-MDMA treatment, EMP-01, for social anxiety disorder, showing a favorable safety profile and meaningful symptom improvement in 49% of participants. 以利波维茨社会焦虑程度衡量,这次双盲、安慰剂控制的试验达到了其主要安全目标,在减少焦虑症状方面显示出有希望的迹象。 The double-blind, placebo-controlled trial met its primary safety goal and demonstrated promising signals in reducing anxiety symptoms, measured by the Liebowitz Social Anxiety Scale. 该公司计划在即将召开的科学会议上提供更详细的数据。 The company plans to present more detailed data at upcoming scientific conferences. 20多年来,在缺乏新的萨达姆(SAD)治疗方法的情况下,结果促使该公司在市场前贸易中的股票增长了5%。 The results, which come amid a lack of new SAD treatments in over two decades, contributed to a 5% rise in the company’s stock in premarket trading.